Assay identifies biomarker of autoimmune encephalitis subtype
Answers from the Lab
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' GABA-A receptor antibody assay aids diagnosis of this serious but treatable condition.
"The disease associated with the GABA-A receptor antibody is very immunotherapy-responsive, if treated early," Dr. McKeon says. However, few reliable testing options are available.
Mayo Clinic Laboratories' new cell-based GABA-A receptor antibody assay doesn't require reflex testing.
"We have a high level of confidence in this testing method," Dr. McKeon says. "It's an opportunity for doctors to be able to diagnose and confirm GABA-A receptor encephalitis, particularly in pediatric patients."
The GABA-A receptor antibody test is recommended — in conjunction with other autoimmune neurology profiles— for specific patients. "The phenotype of note is encephalopathy with seizures," Dr. McKeon says. "Patients also typically have multifocal large cerebral temporal and extra-temporal T2 signal abnormalities without enhancement. If you see patients with that, you should definitely work in GABA-A."
The assay is being launched as a standalone test to accommodate clients' IT systems while enhancing patient care.
Listen to learn more about Mayo Clinic Laboratories' GABA-A receptor antibody assay.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.